secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-07-30T20:01:59+00:00
Accession:  0001664710-26-000043
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros to receive $20M milestone from Takeda; will distribute 25% to stockholders
--------------------------------------------------------------------------------

- $20M milestone triggered by first patient dosed in Phase 3 ELRiSE MDS trial of elritercept vs epoetin alfa for anemia in low-risk MDS.
- Keros to distribute 25% of net cash proceeds from milestone to stockholders after receipt.
- Under existing Takeda license (Jan 2025), Keros already received $200M upfront; total milestones could exceed $1.1B plus tiered royalties.
- Phase 3 ELRiSE MDS trial is open-label, randomized, multicenter; follows positive Phase 2 signals in MDS with/without ring sideroblasts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/0001664710-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/kros-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer